VIRVir Biotechnology, Inc.
$11.71+126% 1Y
$11.71
$5.1252 weeks$11.78
The financials
Vir Biotechnology, Inc. by the numbers
Vir Biotechnology, Inc. (VIR) reported revenue of $239M in Q2 2026 (quarter ended Jun 30, 2026), up 19583% from the same quarter a year earlier. That came with a gross margin of 100% and net income of $80M (34% of revenue). For the full year FY2025, revenue was $69M (−7.6% year on year) and net income −$438M. Its largest product in Q2 2026 was License And Collaboration at $239M, 100% of the disclosed total, well ahead of Grant at 0.0%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $239M | $1.2M | +19583% |
| Gross profit | $239M | $1.2M | +19763% |
| Operating income | $73M | −$118M | to a profit |
| Net income | $80M | −$111M | to a profit |
| Diluted EPS | $0.47 | −$0.80 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| License And Collaboration | $239M | 100% |
| Grant | $11K | 0.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $238.9M
Grant grew -94% year on yearOther -100% year on year
Segment Latestquarter on quarteryear on year
- License And Collaboration$238.9M$238.9Mquarter on quarter n/ayear on year n/an/an/a
- Grant$11.0K$11.0Kquarter on quarter -8.3%year on year -94%-8.3%-94%
- Other$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
On our screens:Most shorted stocks